Profile data is unavailable for this security.
About the company
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
- Revenue in USD (TTM)225.97m
- Net income in USD-15.96m
- Incorporated1996
- Employees281.00
- LocationCerus Corp1220 Concord AvenueCONCORD 94520United StatesUSA
- Phone+1 (925) 288-6000
- Fax+1 (925) 288-6001
- Websitehttps://www.cerus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delcath Systems Inc | 79.60m | 1.20m | 328.77m | 96.00 | 1,070.12 | 2.86 | 235.85 | 4.13 | 0.0087 | 0.0087 | 2.10 | 3.25 | 1.02 | 1.26 | 7.70 | 829,197.90 | 1.54 | -94.54 | 1.90 | -143.97 | 86.29 | 81.31 | 1.50 | -339.85 | 13.71 | -- | 0.00 | -- | 1,701.70 | 88.10 | 44.66 | -- | 87.69 | -- |
| Rxsight Inc | 142.09m | -35.73m | 330.58m | 498.00 | -- | 1.20 | -- | 2.33 | -0.8782 | -0.8782 | 3.50 | 6.72 | 0.4591 | 1.40 | 5.74 | 285,313.30 | -11.54 | -19.50 | -12.45 | -21.50 | 74.98 | 57.17 | -25.15 | -52.00 | 11.44 | -- | 0.0004 | -- | 57.09 | 128.61 | 43.52 | -- | 5.89 | -- |
| Clearpoint Neuro Inc | 34.33m | -23.14m | 403.09m | 115.00 | -- | 24.27 | -- | 11.74 | -0.8264 | -0.8264 | 1.23 | 0.5584 | 0.6829 | 1.95 | 7.52 | 298,539.10 | -46.03 | -35.94 | -54.48 | -41.48 | 61.31 | 63.49 | -67.40 | -74.87 | 5.56 | -92.37 | 0.6479 | -- | 31.04 | 22.85 | 14.37 | -- | 11.41 | -- |
| Myriad Genetics Inc | 825.30m | -400.50m | 418.53m | 2.70k | -- | 1.12 | -- | 0.5071 | -4.34 | -4.34 | 8.97 | 4.00 | 0.9122 | 8.46 | 6.77 | 305,666.70 | -44.27 | -- | -53.15 | -- | 70.36 | -- | -48.53 | -- | 2.12 | -14.93 | 0.2427 | -- | 11.21 | -- | 51.65 | -- | -- | -- |
| Orthopediatrics Corp | 227.41m | -45.61m | 423.56m | 562.00 | -- | 1.21 | -- | 1.86 | -1.96 | -1.96 | 9.74 | 13.93 | 0.4628 | 0.5149 | 4.83 | 404,644.10 | -9.28 | -5.87 | -9.97 | -6.44 | 71.73 | 74.27 | -20.06 | -16.55 | 3.52 | -5.96 | 0.2214 | -- | 37.65 | 23.06 | -80.33 | -- | 4.29 | -- |
| Cerus Corp | 225.97m | -15.96m | 430.28m | 281.00 | -- | 7.00 | -- | 1.90 | -0.0848 | -0.0848 | 1.20 | 0.3201 | 1.12 | 1.99 | 8.35 | 804,163.70 | -7.91 | -20.38 | -12.30 | -31.96 | 60.50 | 61.15 | -7.09 | -25.37 | 1.29 | -1.04 | 0.5772 | -- | 7.78 | 16.51 | 44.20 | -- | -20.50 | -- |
| Standard Biotools Inc | 128.83m | -109.46m | 430.71m | 818.00 | -- | 1.08 | -- | 3.34 | -0.289 | -0.3383 | 0.3399 | 1.04 | 0.211 | 1.97 | 5.27 | 157,490.20 | -17.93 | -29.45 | -22.06 | -35.68 | 47.94 | 50.11 | -84.97 | -79.68 | 4.14 | -- | 0.0008 | -- | 64.03 | 8.27 | -147.67 | -- | 26.98 | -- |
| AngioDynamics, Inc. | 307.31m | -27.71m | 452.15m | 675.00 | -- | 2.59 | -- | 1.47 | -0.6731 | -0.6731 | 7.47 | 4.24 | 1.10 | 2.12 | 7.02 | 455,268.20 | -9.87 | -13.69 | -13.83 | -16.19 | 54.58 | 52.46 | -9.02 | -21.32 | 1.33 | -- | 0.0329 | -- | -3.76 | 2.06 | 81.56 | -- | -10.06 | -- |
| Neuropace Inc | 94.86m | -23.99m | 497.88m | 209.00 | -- | 27.05 | -- | 5.25 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 500.49m | 730.00 | 140.00 | 2.68 | 17.41 | 2.02 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Pacific Biosciences of California Inc | 160.01m | -546.38m | 516.26m | 575.00 | -- | 96.52 | -- | 3.23 | -1.84 | -1.84 | 0.5335 | 0.0177 | 0.1565 | 1.96 | 5.08 | -- | -53.45 | -22.47 | -59.23 | -24.40 | 33.97 | 33.11 | -341.47 | -214.45 | 2.44 | -19.72 | 0.9918 | -- | 3.89 | 15.19 | -76.34 | -- | -- | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 523.69m | 136.00 | -- | 55.68 | -- | 244.82 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
| Orthofix Medical Inc | 818.06m | -119.12m | 529.84m | 1.62k | -- | 1.19 | -- | 0.6477 | -3.04 | -3.04 | 20.82 | 11.20 | 0.9622 | 1.37 | 6.40 | 506,224.00 | -14.01 | -10.81 | -17.28 | -13.34 | 68.27 | 70.31 | -14.56 | -11.57 | 1.38 | -1.35 | 0.2837 | -- | 7.08 | 11.69 | 16.78 | -- | 8.75 | -- |
Data as of Feb 13 2026. Currency figures normalised to Cerus Corp's reporting currency: US Dollar USD
41.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Dec 2025 | 18.20m | 9.48% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 15.88m | 8.27% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 10.01m | 5.21% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.79m | 5.10% |
| Wasatch Advisors LPas of 31 Dec 2025 | 5.46m | 2.84% |
| Amova Asset Management Americas, Inc.as of 31 Dec 2025 | 4.71m | 2.45% |
| Geode Capital Management LLCas of 31 Dec 2025 | 4.49m | 2.34% |
| Silvercrest Asset Management Group LLCas of 30 Sep 2025 | 4.12m | 2.15% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 4.00m | 2.08% |
| Senvest Management LLCas of 31 Dec 2025 | 3.97m | 2.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
